[Clinical experience with tiapride in the treatment of extrapyramidal syndromes].
Tiapride was given at an average dosage of 300-900 mg per day, intramuscularly for the first three days, then by oral route, to 62 patients with abnormal movements of various types. The best responses were recorded in chorea and bucco-lingua-facial dyskinesia as well as in dyskinetic movements induced by levo-dopa in Parkinson patients. Clinical and biological tolerance of tiapride was excellent, with only one case of drowsiness and two cases of galactorrhea.
D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D001549:Benzamides / Q000627:therapeutic use*; D006801:Humans; D013976:Tiapamil Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*
D001549:Benzamides; D013976:Tiapamil Hydrochloride
Expérience clinique du tiapride dans le traitement des syndromes extrapyramidaux.